Please see related commentary by Messmer and Kipps at, Aberrant expression of the epidermal growth factor receptor or the closely related ErbB2 (HEreceptorreceptyrosinesine kinase has been implicated in the formation of various human malignancies [ 1, 2], making these receptors interesting targets for directed anticancer therapeutics.
The resulting compounds show excellent agonistic activity towards the human mu receptor with interesting SAR trends within the series.
This receptor is interesting since it appears that it can function through both reversible and irreversible binding to the receptor.
The absence of E2 binding by the amphioxus estrogen receptor has interesting consequences for the evolution of SRs and ERs.
In that respect, the stress response signature that we detect in HER2-amplified tumours, expressing high levels of ERBB2 receptor, is interesting.
These receptors are interesting targets for a variety of diseases affecting liver, kidney and intestine, in addition to metabolic diseases.
Eph family of receptors are interesting targets for molecular cancer therapy since they are mostly overexpressed in tumors and seem to be involved in tumor cell survival and proliferation, invasion, metastasis, and angiogenesis.
A number of putative receptors for prions have been reported, with one of the most interesting receptors being the 37 kDa laminin receptor precursor (LRP).
We also see other interesting receptors, such as monoamine oxidase B, σ-opioid receptor, β-1 adrenergic receptor, and the glutamate NMDA receptor.
Due to overexpression in many primary human cancers, peptides and peptide receptors remain an interesting candidate for treating cancers through receptor targeting approach [ 36].
